Posted by: | April 15, 2023 | Comments

From their website:

AvidBiotics develops novel, non-antibody proteins as targeted therapeutics against bacteria, viral infections and cancer.

The basis of the company’s technology is specificity – we engineer proteins to specifically bind to targets of interest. In addition, the scaffolds of our proteins exhibit functional potency – e.g., killing that exceeds that of antibodies.


Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required

Terms & Conditions | Privacy Policy | © 2016 The Translational Microbiome Research Forum